Paul Bebbington and Elizabeth Kuipers, two academics whose lives are now impacted by Paul’s diagnosis of Alzheimer’s, offer brave accounts of the day-to-day experiences of living with dementia and being a care provider in an initiative to reduce stigma.
The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
ADI welcomes three new Alzheimer associations, as well as new members to the ADI board.
ADI releases a position paper on the difficult decisions people with dementia, their families and carers are having to make around hospital admission and triage during COVID-19.
Professor Huali Wang of Alzheimer's Disease Chinese (ADC) explains how China has addressed the specific challenges of people living with dementia during COVID-19.
ADI's Global Perspective for February 2020 now available.
Roche announces end of DIAN-TU-001 study after it failed to meets its primary endpoint in people who are affected by early onset Autosomal dominant Alzheimer’s disease.
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.